Although pulmonary fibrosis can occur in the absence of a clear‐cut inciting agent, and
without a clinically clear initial acute inflammatory phase, it is more commonly associated …

Since the initial identification of the novel coronavirus SARS-CoV-2 in December 2019, the
COVID-19 pandemic has become a leading cause of morbidity and mortality worldwide. As …

The SARS-CoV-2 pandemic has already infected in excess of 50 million people worldwide
and resulted in 1.2 million deaths. While the majority of those infected will not have long …

Organization, characterized by fibroblast proliferation, is a common and nearly universal
response to lung injury whether it is focal or diffuse. Despite the vast range of injurious …

In recent decades, advances in nanotechnology engineering have given rise to the rapid
development of many novel applications in the biomedical field. However, studies into the …

The understanding of the pathogenesis of pulmonary fibrosis continues to evolve. The initial
hypothetical model suggested chronic inflammation as the cause of pulmonary fibrosis …

Infection by influenza virus leads to respiratory failure characterized by acute lung injury
associated with alveolar edema, necrotizing bronchiolitis, and excessive bleeding. Severe …

Pulmonary fibrosis (PF), a pathological outcome of chronic and acute interstitial lung
diseases associated to compromised wound healing, is a key component of the “post-acute …

Macrophages are among the most abundant cells in the respiratory tract, and they can have
strikingly different phenotypes within this environment. Our knowledge of the different …

Fibrosis, the result of excess deposition of extracellular matrix (ECM), in particular collagen,
leads to scarring and loss of function in tissues that include the heart, lung, kidney and liver …